
The FDA Just Caught Up To What The Research Community Already Knew
HHS announced April 15 that 12 peptides are moving from Category 2 back to Category 1 for compounding. Here's what that actually means, why nothing has legally changed yet, and why the regulated pathway won't be the affordable pathway for most people.



















